1. Site Top
  2. DesignCell
key visual:DesignCell

DesignCell ®

Treating cancer and other intractable diseases at reasonable cost

  1. Now
    • Cell Survivor Treatment and Regenerative Medicine Clinically Started
  3. 2030
    • The market for cell survivorship treatment and regenerative medicine is growing
  5. 2050

We develop gene modification technology and next-generation automated cell culture technology based on digital x bio fusion to rationalize the cost of advanced medical care, and build a total seamless solution for designed cell pharmaceuticals to overcome intractable diseases such as cancer and realize a society where everyone can live a vibrant life.

Optimizing “CAR-T Cell Therapy” with a DesignCell® Development Platform

CAR-T cell therapy is an innovative cancer treatment that enhances the cancer-attacking ability of T-cells, the key cells to the patient’s own immune system. This therapy works by introducing Chimeric Antigen Receptor (CAR) genes into T cells—immune cells that recognize and attack various foreign...
H
hitachi-rd-en @ hitachi-rd-en
It all started from hereLife sciencesHealthcareDesignCellBackcasting R&DSociety with 100-year active life

What Are “Designed Cells” and Why Are They Attracting Attention?

Hope always exists for better treatments for people suffering from cancer or other intractable diseases. In the spotlight as a therapy that might be able to realize these hopes is gene and cell therapy. This treatment involves cells specially designed to have functional enhancements and then intr...
H
hitachi-rd-en @ hitachi-rd-en
InsightsLife sciencesHealthcareDesignCellBackcasting R&DSociety with 100-year active life

Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT

News release overview Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT Harnessing its automated cell culturing and digital technology to overcome intractable diseases Tokyo, 6 July 2023 – Hitachi, Ltd. (TSE: 6501, "Hitachi") an...
H
hitachi-rd-en @ hitachi-rd-en
News ReleaseLife sciencesBackcasting R&DHealthcareWell-beingSociety with 100-year active lifeDesignCellNews & EventsNews Release（Life sciences）News Release（Healthcare）
See all articles
External announcement

R&D Topics, News Release, Academic conferences, papers, events, etc.

This article is a sponsored article by
''.